Affimed Reports on Corporate Progress and Provides
AFM13 combination with Artiva’s AB-101 NK cells: Received written feedback to pre-investigational new drug (IND) meeting request which supports plan for...
Source: globenewswire.com
Page 2 - Affimednv News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Affimednv . Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Affimednv Today - Breaking & Trending Today
Affimed Provides Updated Clinical Data from Phase 1/2 Study
AFM13 in combination with NK cells shows very high overall and complete response rates in 41 heavily pre-treated CD30-positive Hodgkin lymphoma (HL) and...
Source: globenewswire.com
Affimed Reports Third Quarter 2022 Financial Results
AFM13: Secured access to commercially viable natural killer (NK) cell product to accelerate clinical development of AFM13 and address the high unmet need...
Source: globenewswire.com
Affimed to Report Third Quarter 2022 Financial Results &
HEIDELBERG, Germany, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology...
Source: globenewswire.com
Affimed To Provide a Clinical Update on AFM24 Monotherapy
Selected recommended phase 2 dose (RP2D) of 480 mg with ongoing enrollment in disease-specific cohorts; maximum tolerated dose (MTD) not reachedStable...
Source: globenewswire.com